CAMBRIDGE, Mass. (AP) — Drug developer Curis Inc. said today it will receive a $3 million payment from Debiopharm S.A. for work on a drug candidate aimed at treating cancer.
Curis will receive the payment from its licensee, Debiopharm, because a fifth patient was treated in an early stage study that focused on safety and dosing. T
he drug candidate is Debio 932, formerly called CUDC-305.
Curis’ revenue reached $8.6 million in 2009.
